Group B Streptococcus Type II and Type V Polysaccharide-protein conjugate vaccine

摘要

Antigenic conjugate (A) comprising (1) a capsular polysaccharide (CPS) of type II or V G.B Streptococcus and (2) a protein (I) linked to 2 or more side chains, terminating in sialic acid residues, of CPS through a sec. amino bond is new. CPS has mol.wt. at least 5000. Pref. 5-50% of terminal sialic acid residues are available for linkage to (I); esp. about 7% or 25% for type II or type V CPS respectively. Partic. (I) are tetanus or diphtheria toxoid, or cross reactive material 197.